Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 2,223 shares changed hands during trading, an increase of 69% from the previous session’s volume of 1,312 shares.The stock last traded at $24.50 and had previously closed at $24.36.
Analyst Ratings Changes
Separately, BNP Paribas started coverage on shares of Hikma Pharmaceuticals in a report on Tuesday, May 13th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.
Read Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Up 0.6%
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Read More
- Five stocks we like better than Hikma Pharmaceuticals
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Semtech: Bullish Market Forces Come Into Alignment for This Stock
- What is a SEC Filing?
- Vertical Aerospace: An Analyst’s Roadmap to a Potential Re-Rating
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- New Global Deals Boost These 2 Defense Leaders
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
